Vaccinations have been completed and Valneva expects VALOR trial outcomes to be announced in the first half of 2026, followed by regulatory submissions as planned. Pfizer aims to submit a Biologics ...

Pfizer (PFE) has reportedly decided to sell its entire remaining stake in BioNTech (BNTX), showing a lack of confidence in ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Nirsevimab is a long-acting monoclonal antibody that provides season-long protection against RSV in infants, reducing ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

Pfizer PFE stock has been trading above its 50-day moving average since early November, indicating a potential short-term ...

Anonymized data shared with pharma will remain hidden from public after two-year legal battle, based on hidden evidence of "triangulating" the deceased's identities and assumption their relatives ...

Elevidys now has a “boxed” warning and is no longer available for Duchenne patients who can’t walk. Elsewhere, Nuvalent and Zymeworks unveiled data for targeted cancer drugs.

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Doritos and Cheetos are getting a makeover. PepsiCo said Thursday it’s launching toned-down versions of its bright orange ...